Provides actionable preclinical evidence that an FDA‑approved SGLT2 inhibitor can target NLRP3-driven neuroinflammation and pyroptosis—supporting repurposing potential for disease-modifying PD therapy—while translation is limited by reliance on a single rotenone toxin model and absence of CNS…

By implicating antigen‑specific adaptive immunity against α‑synuclein and defining HLA‑restricted T cell clonotypes and effector programs, the work points to actionable targets (antigen presentation, T cell responses, biomarkers) for immunomodulatory or antigen‑specific therapies relevant to…

Pinpoints TRPV4 as a druggable regulator of autophagic/lysosomal proteostasis (with readouts like LC3B, p62, LAMP1, TFEB), offering a mechanistically actionable target and biomarkers for developing PD therapeutics.

The study supports luteolin as a neuroprotective candidate acting on mitochondria-linked toxin pathology and inflammatory pathways—relevant to PD biology and repurposing—but translational potential is limited by high doses, no PK/α‑synuclein or target-validation data, and reliance on a single toxin…

While the antioxidant, anti-inflammatory and apoptosis-modulating effects are mechanistically relevant to neuroprotection and could inform PD lead discovery, the study is AD-focused, lacks PD-specific targets (α‑synuclein/mitochondria), and has no mammalian validation, limiting immediate…

Provides actionable, translatable targets (vesicular sequestration, DOPAL detoxification, MAO) and supports timing- and multi-target–based neuroprotective strategies to prioritize preclinical and clinical interventions for delaying or preventing Parkinson's disease.

Points to type I IFN/IFNAR1 signaling as a actionable, targetable mechanism linking brain α‑syn pathology to gut inflammation, supporting therapeutic strategies (e.g., IFNAR blockade or JAK inhibition) to limit PD progression along the gut–brain axis.

The paper highlights modifiable, mechanistically plausible targets (dietary bioactives, exercise, gut‑brain and metabolic pathways, mitochondria, inflammation) that could inform multimodal neuroprotective interventions, biomarker selection, and translational studies for Parkinson's despite limited…

By connecting cytoskeletal dysfunction to core PD mechanisms (α-synuclein pathology, mitochondrial quality control) and evaluating actionable interventions and translational challenges, the work identifies concrete targets and strategies useful for drug discovery and target prioritization.

Identifies actionable translational opportunities—nanoparticle delivery to address neuroinflammation, bioenergetics, and gut–brain routes and concrete CMC/PKPD and biomarker needs—making it a useful roadmap for advancing Parkinson's-targeted therapeutics.

Offers actionable preclinical mechanistic evidence that modulating gut microbiota or supplementing SCFAs (butyrate) — and targeting the TLR4/MyD88/NF-κB inflammatory axis — may be a viable therapeutic strategy for PD, though the herbal formula's active constituents remain undefined for direct drug…

Relevance to Parkinson's lies in highlighted, potentially actionable pathways (oral-to-gut microbial translocation, inflammation, BBB and metabolite-mediated neural effects) that could yield novel intervention or biomarker avenues, though the paper is a broad review with limited mechanistic…

Pins HDAC3 as an actionable anti‑inflammatory/anti‑pyroptotic target with in vivo neuroprotection, supporting further preclinical development or repurposing of selective HDAC3 inhibitors for PD therapeutics.

By linking validated mitophagy-related genes to both CNS cell-specific and peripheral immune alterations in PD, the study provides actionable candidate targets and biomarkers for mitochondrial-focused therapeutic development and immune-modulating strategies.

Neuroinflammation and oxidative stress are key drivers of Parkinson's pathology, so TRF's modulation of NF-κB and Nrf2 pathways suggests translational repurposing potential, but lack of PD-specific models and dopaminergic/alpha-synuclein data means focused follow-up is needed.

Targeting microglial inflammation and oxidative stress is relevant to Parkinson's disease neuroprotection, but this study is limited to in vitro BV2 assays without mechanism, active compound identification, or PD-relevant models, so the findings are promising but preliminary for therapeutic…

While not addressing disease modification, the study provides actionable clinical evidence that apomorphine confers broad symptomatic benefits—including non-motor domains—supporting its use, informing endpoint selection for trials, and guiding symptomatic therapeutic strategies despite limited…

For Parkinson's research, the paper highlights actionable pathways linking the microbiome to neuroinflammation and potentially alpha-synuclein pathology and points to readily testable therapeutic and biomarker strategies (dietary modulation, probiotics/FMT, metabolite-targeting drugs) that can be…

Distinguishing disease-driven daytime sleepiness from medication-associated fatigue highlights modifiable targets for symptomatic management and informs therapeutic development and trial stratification for PD non-motor symptoms.

The paper has moderate translational value: it supports routine HUTT screening to prevent falls and to stratify or monitor patients for symptomatic autonomic therapies and clinical trials, but offers limited mechanistic or novel therapeutic-target insights for disease-modifying drug discovery.

Identifies a druggable, inflammation-driven axis (NLRP3) closely tied to core PD pathologies and compiles plant-derived modulators with translational promise, making it a useful roadmap for prioritizing leads and designing preclinical studies.

Synthesizes actionable mechanistic insights and translational therapeutic avenues (immunotherapy, cell replacement, gene therapy), helping researchers prioritize targets, repurposing opportunities, and design of multi-modal, clinically relevant Parkinson’s interventions.

Valuable for therapeutic discovery because it links biologically plausible, inflammation- and proteostasis-targeting mechanisms to early clinical data and clearly identifies manufacturability, potency, and biomarker gaps that must be resolved to enable rigorous disease-modifying MSC trials.

By clarifying how cell type and delivery route map onto distinct mechanisms and clinical goals, the framework aids prioritization of translational strategies, trial design, and selection of biomarkers for PD disease-modifying therapy development.

Highlights TAAR1 as a translationally actionable target to rebalance monoaminergic systems and potentially slow Parkinson's pathology, offering a clear therapeutic focus despite limited direct coverage of PD-specific mechanisms like alpha‑synuclein or mitochondrial dysfunction.